Abstract

Objective
Acute mountain sickness (AMS) affects 25% to 75% of the tens of millions of high altitude travelers annually. Major contributing factors to AMS are hypoxia and nocturnal desaturations. Small studies have found that positive end-expiratory pressure devices are able to prevent and ameliorate AMS, but there have been no controlled trials. The purpose of this study was to assess a single-use nasal strip, Theravent, that provided 5 cm H2
Methods
Healthy, unacclimatized adult participants trekking in the Khumbu region of the Himalayas during Fall 2013 were randomly assigned to Theravent or to a visually identical sham device before their first night sleeping at 4280 m or 4358 m. The primary outcome was AMS incidence, measured by the Lake Louise Score questionnaire, with secondary outcomes of physiologic sleep indices measured by the WatchPAT-200 continuous sleep monitor.
Results
Two hundred nineteen participants were included for intent-to-treat analysis, 115 received PEEP and 104 placebo, with no differences in demographic characteristics between groups. There was no decrease in AMS with the intervention (14% PEEP vs 17% placebo, P = .65, 95% CI: −7% to 14%). The PEEP group reported decreased headache (64% vs 76%, P = .047, OR 0.51, 95% CI: 0.27–0.95) and dizziness (81% vs 98%, P = .024, OR 0.29, 95% CI: 0.09–0.78). The PEEP group showed significant improvement in average oxygen saturation (Sp
Conclusions
Although Theravent had a high rate of user discomfort, this lightweight inexpensive PEEP device may improve some distressing symptoms of AMS and nocturnal oxygenation while sleeping at high altitude.
